<DOC>
	<DOCNO>NCT00435916</DOCNO>
	<brief_summary>This Phase II , open-label , multidose trial SGN-40 design estimate objective response rate assess toxicity patient relapse DLBCL .</brief_summary>
	<brief_title>Study SGN-40 Patients With Relapsed Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Diagnosis DLBCL . Received least one combination chemotherapy regimen rituximab , RCHOP , RESHAP equivalent . Progression relapse since recent therapy . At least one measurable lesion great equal 2 cm conventional CT great equal 1.5 cm spiral CT . Previous diagnosis treatment indolent lymphoma , leptomeningeal lymphoma , central nervous system lymphoma . Primary refractory disease . Received allogenic stem cell transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Antigens , CD40</keyword>
	<keyword>Antibody , Monoclonal</keyword>
	<keyword>Lymphoma , Large B-Cell , Diffuse</keyword>
	<keyword>Lymphoma , Non-Hodgkin</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Immunoproliferative Disorders</keyword>
	<keyword>Lymphatic Diseases</keyword>
	<keyword>Lymphoproliferative Disorders</keyword>
	<keyword>Lymphoma</keyword>
</DOC>